September 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” Different types of human skin cells respond uniquely to various colors and doses of light, which could lead to specialized light treatments for skin conditions.
May 2008 in “10th European Congress of Endocrinology” Ivarmacitinib effectively regrows hair in severe alopecia areata.
3 citations
,
September 2024 in “Dermatology and Therapy” Previous alopecia areata treatments do not affect the long-term effectiveness of ritlecitinib.
14 citations
,
October 2015 in “Neurochemistry International” Letrozole may help prevent seizures by reducing certain hormone levels.
April 2012 in “Journal of the American Academy of Dermatology” Clofazimine effectively treated ashy dermatosis in a patient.
July 2017 in “Nursing2023” Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.
6 citations
,
August 1989 in “European journal of pediatrics” Child with rickets improved with a specific vitamin D therapy, but alopecia did not change.
September 2025 in “Journal of the American Academy of Dermatology” Ritlecitinib may help treat alopecia areata by protecting hair follicles.
173 citations
,
July 2012 in “British Journal of Dermatology” Dabrafenib can cause skin growths and sometimes low-grade skin cancer.
March 2025 in “Scientific Reports” Menthol-based microemulsions improve skin delivery of finasteride and silodosin.
2 citations
,
January 2020 in “Einstein (São Paulo)” Topical tofacitinib shows promise as a future treatment for alopecia areata.
June 2025 in “Indus journal of bioscience research.” Oral tofacitinib is more effective than oral minoxidil for treating alopecia areata.
August 2025 in “ACS Omega” New compounds show promise as nonsteroidal treatments for hair loss.
April 2017 in “Journal of Investigative Dermatology” The document concludes that various topical treatments show promise for skin conditions like atopic dermatitis, psoriasis, and hair loss.
August 2018 in “Journal of Investigative Dermatology” Tofacitinib may help regrow hair in alopecia areata patients.
December 2025 in “The Journal of Dermatology” Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.
January 2008 in “Journal of Medicinal Chemistry” Finasteride may cause sexual and psychological side effects by affecting an enzyme related to epinephrine.
July 2025 in “Journal of Investigative Dermatology” 37 citations
,
May 1997 in “The Journal of Clinical Endocrinology & Metabolism” MK-386 lowers DHT in blood and skin but not in semen.
6 citations
,
November 2017 in “Dermatologic Therapy” Combining mometasone furoate cream with adapalene gel is safer and more effective for hair regrowth in alopecia areata than using the cream alone.
July 2023 in “Dermatology and Therapy” 5-Alpha Reductase Inhibitors are effective for male hair loss and some skin conditions, but their effectiveness in women and safety concerns require careful use.
12 citations
,
March 2014 in “ISRN Pharmacology (Print)” Minoxidil with tretinoin boosts hair growth most effectively, followed by minoxidil alone, and then ketoconazole.
January 2026 in “Vestnik dermatologii i venerologii” Tacrolimus ointment is effective for various skin conditions but needs more research for long-term effects.
May 2025 in “Journal of the Egyptian Womenʼs Dermatologic Society” Vitamin D3 is a safe and effective alternative to steroids for treating alopecia areata, with fewer side effects.
17 citations
,
June 2012 in “European journal of medicinal chemistry” New steroid compounds effectively inhibit 5α-reductase and may treat hair loss.
February 2026 in “Indian Dermatology Online Journal” Tofacitinib significantly improved skin and hair conditions without side effects.
October 2021 in “Meditsinskiy sovet = Medical Council” Cyproterone acetate improves skin symptoms and quality of life in women with androgen-related issues.
3 citations
,
September 2016 in “Dermatologic Therapy” Doxycycline helps prevent skin issues from erlotinib in lung cancer patients.
July 2024 in “Journal of Investigative Dermatology” DS-2325a is safe and well-tolerated, supporting further development for Netherton Syndrome treatment.